ClinicalTrials.gg
Status unknownNCT02471677Updated Jun 22, 2015

Corifollitropin Alfa Versus Follitropin Beta in High Responders

A Phase 4 interventional study of Elonva and Puregon in Infertility, sponsored by Eugonia. Status unknown at 1 site in Greece. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by Eugonia · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2015), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies testing corifollitropin alfa in Infertility — 1 open to participants now, 1 under way, none of them phase 3. corifollitropin alfa · Infertility.

Planned enrollment
16th of 26
62 · median 90
Started
2015
with 2 others
Phase 4
10 of 26
none open now
Registered
22nd of 26
by date
Lead sponsor
1 of 26
Eugonia

Among the 26 studies testing corifollitropin alfa in Infertility, this one is the 16th largest by planned enrollment, is one of 3 that started in 2015, is one of 10 in phase 4, and was the 22nd registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 26 studies testing corifollitropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About corifollitropin alfa

corifollitropin alfa: first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing corifollitropin alfa in Infertility, or all of them as a file.
02

Study summary

The purpose of this randomized controlled trial (RCT) is to compare a single injection of corifollitropin-alfa versus daily injections of follitropin beta regarding the number of oocytes retrieved, hormonal profile and follicle development in patients with high response undergoing ovarian stimulation for in vitro fertilization treatment using a gonadotropin-releasing hormone (GnRH) antagonist protocol combined with GnRH agonist trigger and cryopreservation of all embryos.

Read the detailed description

Corifollitropin alfa, a novel fusion protein lacking luteinizing hormone (LH) activity, has a longer elimination half-life and extended time to peak levels than recombinant follicle stimulating hormone (rFSH). A single injection of corifollitropin alfa may replace seven daily injections follitropin beta during the first week of ovarian stimulation, reducing patient discomfort.

The purpose of this RCT is to compare a single injection of corifollitropin-alfa versus daily injections of follitropin beta regarding the number of oocytes retrieved, as well as hormonal profile and follicle development in patients with high response undergoing ovarian stimulation for IVF using a GnRH antagonist protocol. In addition, incidence of unexpected ovarian hyperstimulation syndrome (OHSS) will be evaluated, although it is anticipated that GnRH agonist triggering will eliminate occurrence of the syndrome.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Ovarian stimulation
  • corifollitropin alfa
  • GnRH antagonist protocol
  • high responders
  • follitropin beta
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-40 years
  • Polycystic ovaries (PCO) or polycystic ovary syndrome (PCOS)
  • no endometriotic cyst

Exclusion criteria

Exclusion Criteria:

  • Patients with poor response
  • Patients using human chorionic gonadotropin (hCG) for triggering final oocyte maturation.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Puregon

    Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles

    Drug: Puregon

  • Experimental
    Elonva

    Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)

    Drug: Elonva

Interventions

  • DrugCorifollitropin alfaStudies of Corifollitropin alfaCorifollitropin alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle

    Also known as: corifollitropin alfa

  • DrugFollitropin betaStudies of Follitropin betaFollitropin beta pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved

    Also known as: follitropin beta

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved

    Time frame: Day of oocyte retrieval (Day 0)

Secondary outcomes

  1. Incidence of severe OHSS

    Time frame: up to 5 days post oocyte retrieval

  2. Follicle development

    Time frame: Day of triggering final oocyte maturation = last day of ovarian stimulation (Day -2 prior to oocyte retrieval)

  3. Fertilization rate

    Time frame: Day 1 after oocyte retrieval

  4. Blastocyst formation rates

    Time frame: Day 5/6 after oocyte retrieval

  5. Number of blastocysts cryopreserved

    Time frame: Day 5/6 after oocyte retrieval

07

Study locations

1 site
  • Eugonia Unit of Assisted Reproduction
    Athens, 11528, Greece
    • Trifon G Lainas, PhD · Contactivf@eugonia.com.gr · 00302107236333
    • Trifon G Lainas, PhD · Principal investigator
08

References and documents

Publications

  • Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009 Dec;24(12):3063-72. doi: 10.1093/humrep/dep291. Epub 2009 Aug 14. Erratum In: Hum Reprod. 2014 May;29(5):1116-20. PubMed 19684043 ↗
  • Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM; Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2010 Nov;21(5):593-601. doi: 10.1016/j.rbmo.2010.06.032. Epub 2010 Jun 30. PubMed 20843746 ↗
  • Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update. 2009 May-Jun;15(3):309-21. doi: 10.1093/humupd/dmn065. Epub 2009 Jan 30. PubMed 19182099 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jun 15, 2015
Start
Sep 2015
Primary completionEst.
Sep 2016
CompletionEst.
Dec 2016
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02471677
Lead sponsor
Eugonia
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Sep 2015
Primary completion
Sep 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Jun 22, 2015

Study contacts

Trifon G Lainas, PhD
Contact
ivf@eugonia.com.gr
00302107236333
Trifon G Lainas, PhD
study director · Eugonia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Corifollitropin alfa

Start the discussion